Enjosim Medical Completes Tens of Millions RMB Pre-A Financing to Set Benchmark for Domestic Injection Pens

VCBeat has exclusively learned that Shanghai ENJOSIM Medical Technology Co., Ltd. (“ENJOSIM”), a platform company specializing in self-administration systems, has recently completed a Pre-A financing round worth tens of millions of yuan.

According to reports, the funds raised in this round of financing will be used to accelerate the commissioning of multiple fully automated production lines at ENJOSIM, support new product development, and expand its domestic and international footprint, thereby further meeting the growing global demand for self-administration systems. Upholding its original mission to break import monopolies and achieve domestic substitution, the ENJOSIM team will assist Chinese pharmaceutical companies in expanding overseas and deliver greater positive value to society.

Driven by favorable factors such as accelerating population aging, rising prevalence of chronic diseases, shifts in disease patterns, the catalytic effect of blockbuster GLP-1 products, and growing demand for self-administration, the global market size for injection pens continues to climb. With the rapid growth in clinical and commercialization demands for innovative peptide and antibody drugs, the injection pen industry is currently facing a situation where supply falls short of demand.

As a critical pharmaceutical packaging component, injection pens are subject to stringent supplier requirements from pharmaceutical manufacturers. Injection pen manufacturers must possess robust and reliable intellectual property rights, controlled injection molding workshops, efficient mold development capabilities, and extensive domestic and international regulatory registration experience to meet customized development needs. Furthermore, companies must be equipped with automated, high-speed assembly production lines to ensure stable, large-scale supply. Most domestic competitors in the injection pen sector remain in the stage of prototype development or small-batch trial production, making it difficult to meet the rapidly growing demands of downstream pharmaceutical clients. The core technical team at ENJOSIM has over 10 years of experience in the research, development, and manufacturing of injection pens, having established an integrated hardware and software customer service platform, and has partnered with more than 20 pharmaceutical companies worldwide.

According to Frost & Sullivan data, the global market size for peptide drugs is projected to grow from USD 62.8 billion in 2020 to USD 96.0 billion in 2025, while the market size for peptide drugs in China is expected to increase from USD 8.5 billion in 2020 to USD 18.2 billion in 2025, indicating substantial market potential. Notably, drugs targeting metabolic diseases via GLP-1 are experiencing explosive growth, with their market size anticipated to reach USD 28.2 billion by 2025.

Amid the third wave of innovation in peptide-based drugs, the entire peptide-related industry chain is gaining momentum. Following the completion of this round of financing, ENJOSIM, backed by the global perspective and resources of professional investment institutions and in collaboration with investors from upstream and downstream industries, will further consolidate and expand its global market presence, set industry benchmarks, and become a stable and reliable partner for peptide drug customers worldwide.

Shanghai ENJOSIM Medical Technology Co., Ltd. is a medical technology enterprise dedicated to the research, development, and manufacturing of self-administration systems. With over a decade of deep industry expertise, its technical team currently offers a range of high-precision pen injectors compatible with biologics such as insulin, GLP-1 agonists, growth hormones, and follicle-stimulating hormones. Headquartered in Shanghai, the company operates a multi-thousand-square-meter industrial manufacturing facility in Wuxi, Jiangsu Province, equipped with Class 100,000 clean assembly workshops and contained assembly workshops. Additionally, ENJOSIM owns independent mold machining and component injection molding factories, enabling an integrated, end-to-end production service for subcutaneous drug delivery devices—from design and development through mold machining, injection molding, to large-scale product assembly. To date, leveraging its robust R&D and manufacturing capabilities, extensive experience in drug-device combination product registration, and comprehensive medical device quality control system, the company has established deep strategic partnerships with dozens of leading global biopharmaceutical enterprises.